Daptomycin Therapy

Introduction to Daptomycin

Daptomycin is a antibiotic that should be used with caution due to potential adverse effects, as recommended by the American Heart Association and the Infectious Diseases Society of America 1, 2, 3

Daptomycin is contraindicated for pneumonia, including pneumonia acquired via aspiration, due to inactivation by pulmonary surfactant, according to the American Heart Association 1, 4
Eosinophilic pneumonia is a serious adverse effect of daptomycin therapy that requires prompt recognition and early discontinuation of daptomycin and initiation of corticosteroids, as recommended by the Infectious Diseases Society of America 4
Daptomycin can cause myopathy, characterized by muscle pain or weakness, elevated muscle enzyme levels, and potential progression to severe muscle damage, particularly at higher doses (≥6 mg/kg/day), as reported in the Clinical Infectious Diseases journal 2, 3, 5

Weekly monitoring of CK levels is recommended during daptomycin treatment, with more frequent monitoring suggested for patients with renal impairment, concurrent medications affecting muscle function, or higher doses of daptomycin (8-12 mg/kg daily), as recommended by the Infectious Diseases Society of America and the Clinical Infectious Diseases guidelines 2, 6
Baseline measurement of creatine phosphokinase (CPK) is required before starting daptomycin therapy to establish reference values, according to the Clinical Infectious Diseases guidelines 6
The following monitoring is necessary for patients on IV daptomycin:
Parameter Frequency
CK levels Weekly
Complete blood count (CBC) Weekly
Renal function Weekly
Liver enzymes Weekly
Higher doses of daptomycin may be used for specific infections, such as VRE bloodstream infections or prosthetic joint infections, but require careful consideration to minimize the risk of myopathy, as recommended by the Infectious Diseases Society of America and the Clinical Infectious Diseases guidelines 2, 3, 5

Daptomycin should be discontinued in patients with myopathy or elevated creatine phosphokinase (CPK) levels, and alternative antibiotics like linezolid, quinupristin-dalfopristin, or telavancin should be considered for MRSA infections, as recommended by the American Heart Association and the Infectious Diseases Society of America 1, 2, 3
Guideline societies, including the American College of Cardiology and the Infectious Diseases Society of America, recommend careful consideration of daptomycin dosing to minimize the risk of myopathy, according to the Clinical Infectious Diseases guidelines 5